Roche’s Corona drug achieves desired effect in study

Patients who received Actemra / RoActemra plus standard treatment were 44 percent less likely to be hooked up to the ventilator or to die compared to those who received placebo plus standard treatment. The Basel pharmaceutical giant announced this on Friday.

Roche will also launch an antibody test that can be used to identify people who have been infected with the coronavirus and who have already developed antibodies. The test could play an important role in characterizing a vaccine-induced immune response, Roche said.